KR101379930B1 - 후발성 백내장 억제용 조성물 및 이의 제조 방법 - Google Patents

후발성 백내장 억제용 조성물 및 이의 제조 방법 Download PDF

Info

Publication number
KR101379930B1
KR101379930B1 KR1020110133103A KR20110133103A KR101379930B1 KR 101379930 B1 KR101379930 B1 KR 101379930B1 KR 1020110133103 A KR1020110133103 A KR 1020110133103A KR 20110133103 A KR20110133103 A KR 20110133103A KR 101379930 B1 KR101379930 B1 KR 101379930B1
Authority
KR
South Korea
Prior art keywords
sulfasalazine
composition
hyaluronic acid
cataract
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020110133103A
Other languages
English (en)
Korean (ko)
Other versions
KR20130066319A (ko
Inventor
백영준
주천기
이성희
최준섭
우구
Original Assignee
가톨릭대학교 산학협력단
(주)한국비엠아이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020110133103A priority Critical patent/KR101379930B1/ko
Application filed by 가톨릭대학교 산학협력단, (주)한국비엠아이 filed Critical 가톨릭대학교 산학협력단
Priority to US14/364,325 priority patent/US9364552B2/en
Priority to IN5738DEN2014 priority patent/IN2014DN05738A/en
Priority to JP2014547077A priority patent/JP5843975B2/ja
Priority to CA2858699A priority patent/CA2858699A1/en
Priority to PCT/KR2012/000205 priority patent/WO2013089307A1/ko
Priority to BR112014014038A priority patent/BR112014014038A2/pt
Priority to EP12858133.7A priority patent/EP2792356A4/en
Priority to CN201280069538.7A priority patent/CN104168901A/zh
Publication of KR20130066319A publication Critical patent/KR20130066319A/ko
Application granted granted Critical
Publication of KR101379930B1 publication Critical patent/KR101379930B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
KR1020110133103A 2011-12-12 2011-12-12 후발성 백내장 억제용 조성물 및 이의 제조 방법 Active KR101379930B1 (ko)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020110133103A KR101379930B1 (ko) 2011-12-12 2011-12-12 후발성 백내장 억제용 조성물 및 이의 제조 방법
IN5738DEN2014 IN2014DN05738A (https=) 2011-12-12 2012-01-09
JP2014547077A JP5843975B2 (ja) 2011-12-12 2012-01-09 後発性白内障抑制用組成物およびその製造方法
CA2858699A CA2858699A1 (en) 2011-12-12 2012-01-09 Composition for inhibiting after-cataract and method of preparing the same
US14/364,325 US9364552B2 (en) 2011-12-12 2012-01-09 Composition for inhibiting after-cataract and method of preparing the same
PCT/KR2012/000205 WO2013089307A1 (ko) 2011-12-12 2012-01-09 후발성 백내장 억제용 조성물 및 이의 제조 방법
BR112014014038A BR112014014038A2 (pt) 2011-12-12 2012-01-09 composição para inibição do pós-cirúrgico de catarata e método para preparação da mesma
EP12858133.7A EP2792356A4 (en) 2011-12-12 2012-01-09 COMPOSITION FOR INHIBITING AFTERSTAR AND METHOD FOR THE PRODUCTION THEREOF
CN201280069538.7A CN104168901A (zh) 2011-12-12 2012-01-09 后发性白内障抑制用组合物及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110133103A KR101379930B1 (ko) 2011-12-12 2011-12-12 후발성 백내장 억제용 조성물 및 이의 제조 방법

Publications (2)

Publication Number Publication Date
KR20130066319A KR20130066319A (ko) 2013-06-20
KR101379930B1 true KR101379930B1 (ko) 2014-04-14

Family

ID=48612735

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110133103A Active KR101379930B1 (ko) 2011-12-12 2011-12-12 후발성 백내장 억제용 조성물 및 이의 제조 방법

Country Status (9)

Country Link
US (1) US9364552B2 (https=)
EP (1) EP2792356A4 (https=)
JP (1) JP5843975B2 (https=)
KR (1) KR101379930B1 (https=)
CN (1) CN104168901A (https=)
BR (1) BR112014014038A2 (https=)
CA (1) CA2858699A1 (https=)
IN (1) IN2014DN05738A (https=)
WO (1) WO2013089307A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101379930B1 (ko) 2011-12-12 2014-04-14 가톨릭대학교 산학협력단 후발성 백내장 억제용 조성물 및 이의 제조 방법
KR101412776B1 (ko) * 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 각결막염 치료용 점안제 조성물 및 이의 제조 방법
KR101895950B1 (ko) * 2015-12-18 2018-09-06 (주)한국비엠아이 골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법
US11376266B2 (en) 2016-01-06 2022-07-05 Keio University Antitumor agent
US10385096B2 (en) * 2016-08-30 2019-08-20 Council Of Scientific & Industrial Research Pro-Amb reverse turn restricted bioactive peptide analogues
CA3181327A1 (en) 2016-11-10 2018-05-17 Medisca Pharmaceutique Inc. Pharmaceutical compounding methods and systems
US11026460B2 (en) * 2017-03-03 2021-06-08 Stormy McCowen TAYLOR Hair filler device
CN116172885B (zh) * 2021-12-17 2025-10-28 河南省人民医院 一种抗后发性白内障药物制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100894042B1 (ko) * 2007-04-13 2009-04-20 가톨릭대학교 산학협력단 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093487A (en) * 1986-01-06 1992-03-03 Mobay Corporation Low viscosity high molecular weight filter sterilizable hyaluronic acid
KR100490286B1 (ko) 2001-09-12 2005-05-17 주식회사 뉴로테크 설파살라진을 활성성분으로 함유하는 것을 특징으로 하는망막손상 치료용 안약 조성물과 그 제조방법
MXPA05000533A (es) 2002-08-07 2005-04-19 Medidom Lab Proceso para preparar una formulacion esteril de acido hialuronico de alto peso molecular.
KR20030069917A (ko) 2003-06-27 2003-08-27 주식회사 뉴로테크 안질환 예방 및 치료용 약학적 조성물
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
CN102106838A (zh) 2009-12-23 2011-06-29 上海信谊嘉华药业有限公司 一种柳氮磺吡啶肠溶制剂及其制备方法
CN102225220A (zh) 2011-06-14 2011-10-26 天津晶明新技术开发有限公司 眼科手术粘弹剂
KR101379930B1 (ko) 2011-12-12 2014-04-14 가톨릭대학교 산학협력단 후발성 백내장 억제용 조성물 및 이의 제조 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100894042B1 (ko) * 2007-04-13 2009-04-20 가톨릭대학교 산학협력단 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물

Also Published As

Publication number Publication date
US9364552B2 (en) 2016-06-14
BR112014014038A2 (pt) 2017-06-13
JP5843975B2 (ja) 2016-01-13
EP2792356A4 (en) 2015-11-11
JP2015500334A (ja) 2015-01-05
EP2792356A1 (en) 2014-10-22
CN104168901A (zh) 2014-11-26
WO2013089307A1 (ko) 2013-06-20
CA2858699A1 (en) 2013-06-20
US20140378410A1 (en) 2014-12-25
KR20130066319A (ko) 2013-06-20
IN2014DN05738A (https=) 2015-04-10

Similar Documents

Publication Publication Date Title
KR101379930B1 (ko) 후발성 백내장 억제용 조성물 및 이의 제조 방법
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
KR101433152B1 (ko) 안과용 약물의 전달에 유용한 젤
EP3179982B1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
TW201105363A (en) Eye drop for macular edema treatment
US10279046B2 (en) Eye drop composition for treating ocular inflammatory disease and preparation method therefor
JP2023075278A (ja) 薬剤送達用生体溶解性医薬ゲル
KR100894042B1 (ko) 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물
KR20000049136A (ko) 후발 백내장 억제제
KR101507504B1 (ko) 안구건조증 및 관련 안과 질환의 치료용 점안제 조성물 및 이의 제조 방법
KR101840256B1 (ko) 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101723703B1 (ko) 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물
CA3088185C (en) Suspension compositions of multi-target inhibitors
EP2758031A1 (en) Ophthalmic gel compositions
US20250134849A1 (en) Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin
US20260007595A1 (en) Eye drop formulations containing chondroitin sulfate for relieving ocular pain or discomfort
CN103167875A (zh) 用于治疗角膜浑浊的ep2或ep4激动剂
AU2023255001A1 (en) Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin
CA3217868A1 (en) Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin
EP4282402A1 (en) Ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis through eye drop administration
JP3504656B2 (ja) 水性医薬組成物
CN120478277A (zh) 吡贝地尔滴眼液药物组合物及其用途
CN117503691A (zh) 一种具有减轻老视作用的长效眼用制剂
CN120305202A (zh) 一种硝酸毛果芸香碱眼用药物组合物
KR20000013487A (ko) 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20170316

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180420

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190220

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20200131

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20210129

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20220218

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 13